1Calvert H.An overview of folate metabolism:Features relevant to the action and toxicities of antifolate anticancer agents[J].Semin Oncol,1999,26(2Suppl6):3.
3Taylor P,Castagneto B,Dark G,et al.Single-agent pemetrexed for chemona? ve and pretreated patients with malignant pleural mesothelioma:results of an International Expanded Access Program[J].Thorac Oncol,2008,3(7):764-771.
4Athanasios X,Torsten TB,Torsten GB,et al.Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma:an observational study[J].Occup Med Toxicol,2008,3:34.
5Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
6Heist RS,Fidias P,Huberman M,et al.A phase II study of oxaliplatin,pemetrexed,and bevacizumab in previously treated advanced non-small cell lung cancer[J].J Thorac Oncol,2008,3(10):1153-1158.
7Sun JM,Lee KW,Kim Jh,et al.Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer[J].Jpn J Clin Oncol,2009,39(1):27-32.
8Llombart-Cussac A,Theodoulou M,Rowland K,et al.Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment:phase Ⅱ study[J].Clin Brest Cancer,2006,7(5):380-385.
9Matulonis UA,Horowitz NS,Campos SM,et al.Phase Ⅱ study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer[J].J Clin Oncol,2008,26(35):5761-5766.
10Celio L.Multicenter phase Ⅱ study of pemetrexed and oxali-platin as first-line therapy in advanced gastric cancer[J].Proc ASCO,2006,14:45.
7Ciuleanu T, Brodowicz T, Zielinski C, et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a rando- mised, double-blind, phase 3 study[J]. Lancet, 2009, 374 (9699):1432-1440.
8Bookman M A. First-line Chemotherapy in epithelial ovarian cancer [J]. Clin Obstet Gynecol, 2012, 55(1): 96-113.
9Chattopadhyay S, Moran R G, Goldman I D. Pemetrexed: biomedical and cellular pharmacology, mechanisms, and clinical applications. [J]. Mol Cancer Ther, 2007, 6: 404- 417.
10Vogelzang N J, Rusthoven J J, Symanowski J, et al. Phase III study of pemetrexed in combination with eisplatin versus eisplatin alone in patients with malignant pleural mesothelioma [J]. J Clin Oncol, 2003, 21(14): 2636-2644.
